Skip to main content


29 Feb 2024: Rare Disease Day at ICMAB!

We are happy to celebrate the Rare Disease Day and to highlight that we continue with our effort to develop a more effective treatment for Fabry disease. In the frame of the European projects Phoenix (#953110) and the recently granted Nano4Rare (#101136772), Nanomol-bio group expects to mature the development of our innovative nanopharmaceutical product named nanoGLA up to First-in-Human clinical trial.

29 February 2024

NanoGLA achieved the Orphan Drug Designation by the European Commission in January 2021 for the treatment of Fabry disease, thanks to the superior efficacy this product demonstrated at preclinical level compared to the marketed products based on Enzyme Replacement Therapy. This was an important milestone achieved in the frame of the EU Smart4Fabry project (#720942) (2017-2020) under the coordination of ICMAB-CSIC team, also belonging to CIBER-BBN network.


Hits: 623